Muramyl dipeptide mitigates obesity-induced insulin resistance by targeting nucleotide-binding oligomerization domain-containing protein 2 (NOD2) and interferon regulatory factor 4 (IRF4) [239]. Here, IRF4 is linked to obesity due to melanocortin 4 receptor deficiency.